Teclistamab | MagisTEC1 | ASCO2022 | Is this trial practicing changing?

Vinay Prasad, MD MPH; Physician & Associate Professor

Follow me on:
Twitter @vprasadmdmph

[caroldean]

I've been to ASCO and it's overwhelming. So nice to be able to just browse some of the stuff that impacts my job.

[looliaj]

God, I love you VP!! We will all look back 20 yrs from now and think how stupid of the medical institutions not to use your genius and prolific publications to teach their students proper literature appraisal and critical thinking. Thank you!
I learn more from you every day with little time in clinic than all the other promoted garbage by authors with ginormous COIs.

[christopherdasaro]

When the “medical writers” slide popped up I almost spit out my coffee, such a hilarious repeat offense

[oldmango]

still energized----an understatement. thanks for the knowledge

[nickmullen]

That adverse effect table is pretty striking. A quarter of all patients had grade 3 or 4 pneumonia or SARS-CoV-2 infection. 64% grade 3 or 4 neutropenia. Yikes!

[janetmcburney]

Does is seem as though this group of monoclonal antibodies are showing major promise?

[danielsharon]

Never had an issue w/your tone. You tell it like it is when it comes to researchers and PH "experts."

[KILLRSxRAGE]

If they can’t handle the heat then get out of clinical trials. It’s a shame they amount of garbage trials we have and pay for.